title: Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients.
abstract: BACKGROUND
  Improvements in ventilatory mechanics with tiotropium increases exercise tolerance during pulmonary rehabilitation. We wondered whether tiotropium also increased physical activities outside of pulmonary rehabilitation.
  
  
  METHODS
  COPD patients participating in 8 weeks of pulmonary rehabilitation were studied in a randomized, double-blind, placebo-controlled trial of tiotropium 18 microg daily (tiotropium = 47, placebo = 44). Study drug was administered for 5 weeks prior to, 8 weeks during, and 12 weeks following pulmonary rehabilitation. Patients completed a questionnaire documenting participation in pre-defined activities outside ofpulmonary rehabilitation during the 2 weeks prior to each visit. Patients who submitted an activity questionnaire at week 4 and on at least one subsequent visit were included in the analysis. For each patient, the number of sessions was multiplied with the duration of each activity and then summed to give overall activity duration.
  
  
  RESULTS
  Patients (n = 46) had mean age of 67 years, mean baseline FEVJ of 0.84 L (33% predicted). Mean (SE) increase in duration of activities (minutes during 2 weeks prior to each visit) from week 4 (prior to PR) to week 13 (end of PR) was 145 (84) minutes with tiotropium and 66 (96) minutes with placebo. The increase from week 4 to week 25 (end of follow-up) was 262 (96) and 60 (93) minutes for the respective groups. Increases in activity duration from week 4 to weeks 17, 21, and 25 were statistically significant with tiotropium. No statistical differences over time were observed within the placebo-treated group and differences between groups were not significant.
  
  
  CONCLUSIONS
  Tiotropium appears to amplify the effectiveness of pulmonary rehabilitation as seen by increases in patient self-reported participation in physical activities.
authors.affiliation: Boehringer Ingelheim GmbH, Ingelheim, Germany. ; 2Harbor-UCLA Medical Center, Torrance, CA, USA. skesten@ing.boehringer-ingelheim.com
authors.forename: Steven
authors.initials: S
authors.lastname: Kesten
authors.forename: Richard
authors.initials: R
authors.lastname: Casaburi
authors.forename: David
authors.initials: D
authors.lastname: Kukafka
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Cooper
mesh_terms: D000368:Aged; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D015444:Exercise; D017079:Exercise Tolerance; D005260:Female; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume; D015438:Health Behavior; D006801:Humans; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000523:psychology / Q000534:rehabilitation*; D012602:Scopolamine Derivatives / Q000627:therapeutic use*; D012647:Self-Assessment; D000069447:Tiotropium Bromide
chemical_list: D001993:Bronchodilator Agents; D012602:Scopolamine Derivatives; D000069447:Tiotropium Bromide